Literature DB >> 15164999

New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

R A Ajjan1, A P Weetman.   

Abstract

Cytokines play a key role in the development of Graves' ophthalmopathy (GO). These molecules are produced in the orbit of GO patients by infiltrating inflammatory cells as well as orbital fibroblasts. Locally produced cytokines stimulate fibroblast proliferation and their production of glycosaminoglycans, which result in accumulation of extracellular matrix and oedema with consequent proptosis. In addition to these direct effects, cytokines can modulate the immune reaction in GO by increasing major histocompatibility complex (MHC) class II, adhesion molecules, CD40, prostaglandin and heat shock protein expression in the orbit, thereby having a role in localising and augmenting the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164999     DOI: 10.1007/BF03345272

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  45 in total

Review 1.  Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yuji Hiromatsu; Hiroo Kaku; Ikuyo Miyake; Shiro Murayama; Eri Soejima
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

Review 2.  Animal models of Graves' disease.

Authors:  M Ludgate
Journal:  Eur J Endocrinol       Date:  2000-01       Impact factor: 6.664

Review 3.  The concept of type-1 and type-2 helper T cells and their cytokines in humans.

Authors:  G Del Prete
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

Review 4.  Eyeing up Graves' ophthalmopathy.

Authors:  A P Weetman
Journal:  Mol Cell Endocrinol       Date:  1997-02-07       Impact factor: 4.102

5.  Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients.

Authors:  R Lu; P Wang; L Wartofsky; B D Sutton; J L Zweier; R S Bahn; J Garrity; K D Burman
Journal:  Thyroid       Date:  1999-03       Impact factor: 6.568

6.  Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy.

Authors:  L C Hofbauer; T Mühlberg; A König; G Heufelder; H D Schworm; A E Heufelder
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

7.  Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease.

Authors:  S Costagliola; M C Many; J F Denef; J Pohlenz; S Refetoff; G Vassart
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

8.  Cell-mediated or humoral immunity in Graves' ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue.

Authors:  S M McLachlan; M F Prummel; B Rapoport
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

9.  Interferon-gamma gene microsatellite polymorphisms in patients with Graves' disease.

Authors:  T Siegmund; K H Usadel; H Donner; J Braun; P G Walfish; K Badenhoop
Journal:  Thyroid       Date:  1998-11       Impact factor: 6.568

10.  Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts.

Authors:  C Balazs; H Kiss; N R Farid
Journal:  Horm Metab Res       Date:  1998-08       Impact factor: 2.936

View more
  13 in total

1.  Graves' ophthalmopathy: search for shared autoantigen(s) continues.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

2.  Currently available somatostatin analogs are not good for Graves' orbitopathy.

Authors:  M L Tanda; L Bartalena
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Authors:  L Bartalena; M L Tanda
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 4.  The thyroid, the eyes and the gut: a possible connection.

Authors:  D Covelli; M Ludgate
Journal:  J Endocrinol Invest       Date:  2017-01-07       Impact factor: 4.256

Review 5.  Insights into the role of fibroblasts in human autoimmune diseases.

Authors:  T J Smith
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

6.  In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.

Authors:  Hee Young Choi; Ji Eun Lee; Ji Woong Lee; Hyun Jun Park; Ji Eun Lee; Jae Ho Jung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-22       Impact factor: 2.671

Review 7.  Graves' ophthalmopathy: state of the art and perspectives.

Authors:  L Bartalena; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

8.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

9.  Association of IL12B polymorphisms with susceptibility to Graves ophthalmopathy in a Taiwan Chinese population.

Authors:  Yu-Huei Liu; Ching-Chu Chen; Li-Ling Liao; Lei Wan; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2012-11-19       Impact factor: 8.410

10.  Graves' ophthalmopathy: a review of immunogenetics.

Authors:  Omid Khalilzadeh; Sina Noshad; Armin Rashidi; Aliakbar Amirzargar
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.